EUVIMEDEUVIMED entdecken
Crossref

Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer and High Oncotype DX Recurrence Scores

Inimfon Jackson iD, Xiudong Lei, Marija Sullivan iD, Carlos H Barcenas iD, Sharon H Giordano iD, Mariana Chavez-MacGregor iD

JCO Oncology Practice · 28.04.2026

DOI: 10.1200/op-25-01106 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCO Oncology Practice, online erschienen am 28.04.2026. Verfasst von Inimfon Jackson und 5 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX. Die Arbeit nennt 50 Literaturangaben.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Although the 21-gene Oncotype DX assay predicts chemotherapy (CT) benefit in hormone receptor (HR)–positive, human epidermal growth factor receptor 2 (HER2)–negative breast cancer (BC), some patients decline CT despite their physician recommendations. We examined factors associated with CT declination and its impact on overall survival (OS) among patients with early-stage disease and high recurrence scores (RS). METHODS Patients aged 18 years and older diagnosed with clinical stage I-II HR-positive/HER2-negative BC who underwent definitive surgery between 2018 and 2022 and had RS > 25 were identified in the National Cancer Database. Multivariable logistic regression was used to identify factors associated with CT declination. Multivariable Cox proportional hazards regression was used to examine the association between CT declination and OS in a 1:5 propensity score–matched cohort. RESULTS Among 30,326 patients with RS > 25, 10.9% declined CT. 15.5% of patients who declined CT also declined hormonal therapy. Higher RS was associated with lower odds of CT declination (adjusted odds ratio [aOR], 0.97; 95% CI, 0.96 to 0.97). A more recent year of diagnosis and Hispanic race (aOR, 0.83; 95% CI, 0.70 to 0.98) were associated with lower odds of CT declination, while older age and Black race (aOR, 1.29; 95% CI, 1.15 to 1.45) were associated with higher odds. Patients on Medicaid (aOR, 1.53; 95% CI, 1.31 to 1.79) and Medicare (aOR, 1.19; 95% CI, 1.05 to 1.34) had higher odds of declination compared with those on private insurance. Having pathologic Nodal 1 (pN1) disease was associated with lower odds of declination than pN0 disease. Notably, CT declination was associated with an increased risk of death (aHR, 1.43; 95% CI, 1.20 to 1.69). CONCLUSION Despite a decrease in CT declination over time, disparities persist, and declination is associated with worse OS. Further research is needed to understand these disparities and improve cancer care delivery and outcomes.

Autor:innen und Institutionen

  • Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Health Services Research, The University of Texas MD Anderson Cancer Center, Houston, TX.
  • Department of Breast Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.

ORCID-Profile: Inimfon Jackson, Marija Sullivan, Carlos H Barcenas, Sharon H Giordano, Mariana Chavez-MacGregor

Zitieren

APA

Jackson, I., Lei, X., Sullivan, M., Barcenas, C. H., Giordano, S. H., & Chavez-MacGregor, M. (2026). Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer and High Oncotype DX Recurrence Scores. JCO Oncology Practice. https://doi.org/10.1200/op-25-01106

Vancouver

Jackson I, Lei X, Sullivan M, Barcenas CH, Giordano SH, Chavez-MacGregor M. Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer and High Oncotype DX Recurrence Scores. JCO Oncology Practice. 2026. doi:10.1200/op-25-01106

BibTeX
@article{Jackson2026,
  author = {Jackson, Inimfon and Lei, Xiudong and Sullivan, Marija and Barcenas, Carlos H and Giordano, Sharon H and Chavez-MacGregor, Mariana},
  title = {Chemotherapy Declination Among Patients With Early-Stage Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Breast Cancer and High Oncotype DX Recurrence Scores},
  journal = {JCO Oncology Practice},
  year = {2026},
  doi = {10.1200/op-25-01106}
}
Kostenlos starten →